
Verve Therapeutics, a Cambridge biotech that wants to use gene-editing to lower cholesterol, said Thursday that it has raised $63 million in venture capital to advance an experimental approach to fighting heart disease.
The company raised $60 million in venture capital in its first fundraising effort less than two years ago. Verve was officially launched in May 2019 and has financial backing from a number of well-known venture capitalists, including GV, formerly Google Ventures.
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.